PTC Therapeutics, Inc. (PTCT) Financials
PTCT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 1.8 billion | 2.7 billion |
2023-12-31 | 1.9 billion | 2.7 billion |
2023-09-30 | 1.3 billion | 1.9 billion |
2023-06-30 | 1.3 billion | 1.9 billion |
PTCT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 6.4 million | 18.4 million |
2023-12-31 | -128.8 million | 16.5 million |
2023-09-30 | -43.7 million | 56.5 million |
2023-06-30 | -33.4 million | 29.4 million |
PTCT Net Income
No data available :(
PTCT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | - | - | 136.9 million |
2023-12-31 | 876.7 million | - | 130.8 million |
2023-09-30 | 294.8 million | - | 131.2 million |
2023-06-30 | 337.9 million | 572.6 million | 130.0 million |
PTCT Shares Outstanding
PTCT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 64.4 million | 116.1 million | 73.3 million | - |
2023-12-31 | 28.5 million | 121.4 million | 80.9 million | -4.6 million |
2023-09-30 | 29.2 million | 164.2 million | 80.9 million | - |
2023-06-30 | 19.3 million | 185.9 million | 40.5 million | - |
PTCT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 210.1 million | 14.7 million |
2023-12-31 | 307.1 million | 106.3 million |
2023-09-30 | 196.6 million | 9.5 million |
2023-06-30 | 213.8 million | 12.7 million |
PTCT
Price: $32.96
52 week price:
Earnings Per Share: -8.37 USD
P/E Ratio: -2.79
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 588300
Ebitda: -20.6 millionMarket Capitalization: 2.6 billion